BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

...regenerative antibody platform (see “Selective Regeneration”).Extrachromosomal DNA associated with poor cancer outcomesA team led by Boundless Bio...
...types analyzed. Boundless is developing small molecules to destroy cancer cells that depend on ecDNA (see “Boundless Bio”).Gladstone...
...integration site family member 3A ZNRF3 – Zinc and ring finger 3 Danielle Golovin Merck & Co. Inc. Gladstone Institutes Boundless Bio Surrozen Institute...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...hired Richard Morris as CFO. He was EVP and CFO at Context Therapeutics. Cancer company Boundless Bio...
...which is targeting extrachromosomal DNA, launched in September with a $46.4 million series A (see “Boundless Bio...
BioCentury | Sep 20, 2019
Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

...a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio...
...Diego professor, teamed up with Scripps Research professor and serial entrepreneur Ben Cravatt to launch Boundless Bio...
...selection. Hornby isn’t aware of any other companies working on ecDNA for cancer. COMPANY PROFILE Boundless Bio...
Items per page:
1 - 3 of 3
BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

...regenerative antibody platform (see “Selective Regeneration”).Extrachromosomal DNA associated with poor cancer outcomesA team led by Boundless Bio...
...types analyzed. Boundless is developing small molecules to destroy cancer cells that depend on ecDNA (see “Boundless Bio”).Gladstone...
...integration site family member 3A ZNRF3 – Zinc and ring finger 3 Danielle Golovin Merck & Co. Inc. Gladstone Institutes Boundless Bio Surrozen Institute...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...hired Richard Morris as CFO. He was EVP and CFO at Context Therapeutics. Cancer company Boundless Bio...
...which is targeting extrachromosomal DNA, launched in September with a $46.4 million series A (see “Boundless Bio...
BioCentury | Sep 20, 2019
Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

...a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio...
...Diego professor, teamed up with Scripps Research professor and serial entrepreneur Ben Cravatt to launch Boundless Bio...
...selection. Hornby isn’t aware of any other companies working on ecDNA for cancer. COMPANY PROFILE Boundless Bio...
Items per page:
1 - 3 of 3